JP2017509585A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509585A5
JP2017509585A5 JP2016541595A JP2016541595A JP2017509585A5 JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5 JP 2016541595 A JP2016541595 A JP 2016541595A JP 2016541595 A JP2016541595 A JP 2016541595A JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5
Authority
JP
Japan
Prior art keywords
formula
salt
compound
providing
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541595A
Other languages
English (en)
Japanese (ja)
Other versions
JP6425727B2 (ja
JP2017509585A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071319 external-priority patent/WO2015100145A1/en
Publication of JP2017509585A publication Critical patent/JP2017509585A/ja
Publication of JP2017509585A5 publication Critical patent/JP2017509585A5/ja
Application granted granted Critical
Publication of JP6425727B2 publication Critical patent/JP6425727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541595A 2013-12-23 2014-12-18 大環状hcv ns3阻害トリペプチド Active JP6425727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920446P 2013-12-23 2013-12-23
US61/920,446 2013-12-23
PCT/US2014/071319 WO2015100145A1 (en) 2013-12-23 2014-12-18 Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide

Publications (3)

Publication Number Publication Date
JP2017509585A JP2017509585A (ja) 2017-04-06
JP2017509585A5 true JP2017509585A5 (enExample) 2018-01-18
JP6425727B2 JP6425727B2 (ja) 2018-11-21

Family

ID=52278856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541595A Active JP6425727B2 (ja) 2013-12-23 2014-12-18 大環状hcv ns3阻害トリペプチド

Country Status (20)

Country Link
US (2) US9440991B2 (enExample)
EP (1) EP3087085B1 (enExample)
JP (1) JP6425727B2 (enExample)
KR (1) KR102366697B1 (enExample)
CN (3) CN105849118B (enExample)
AR (1) AR098959A1 (enExample)
AU (1) AU2014370125B2 (enExample)
CA (1) CA2934537C (enExample)
EA (1) EA201691031A1 (enExample)
ES (1) ES2724460T3 (enExample)
IL (1) IL246064A0 (enExample)
MX (1) MX2016008452A (enExample)
NZ (1) NZ720745A (enExample)
PL (1) PL3087085T3 (enExample)
PT (1) PT3087085T (enExample)
SG (1) SG11201604482QA (enExample)
SI (1) SI3087085T1 (enExample)
TR (1) TR201906413T4 (enExample)
TW (3) TWI762003B (enExample)
WO (1) WO2015100145A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9809576B1 (en) 2014-07-18 2017-11-07 Abbvie Inc. Synthetic route to anti-viral agents
US9809534B1 (en) * 2014-07-21 2017-11-07 Abbvie Inc. Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en) 2015-01-30 2019-06-11 Abb Vie Inc. Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
US10450291B2 (en) 2015-06-29 2019-10-22 Central Glass Company, Limited Method for producing fluorine-containing cyclopropane carboxylic acid compound
JP2020505952A (ja) 2017-02-01 2020-02-27 アッヴィ・インコーポレイテッド (±)−2−(ジフルオロメチル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸及び(±)−2−(ビニル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸の酵素的製造方法
WO2019084740A1 (zh) * 2017-10-31 2019-05-09 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) * 2017-10-31 2018-02-27 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107827748A (zh) * 2017-11-14 2018-03-23 安徽华胜医药科技有限公司 一种乙酸2‑烯丙基环丙酯消旋体的合成方法
KR102519417B1 (ko) 2018-11-28 2023-04-10 삼성디스플레이 주식회사 스트레처블 표시 장치
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
CN116041181A (zh) * 2023-01-04 2023-05-02 广州巨元生化有限公司 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006125446A (ru) * 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EP2540349B1 (en) * 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2289880A1 (en) * 2009-07-08 2011-03-02 Bayer CropScience AG 2-Pyridinylcyclopropylbenzamide fungicides
SG188618A1 (en) * 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2015095430A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
ES2708993T3 (es) * 2013-12-23 2019-04-12 Gilead Sciences Inc Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC

Similar Documents

Publication Publication Date Title
JP2017509585A5 (enExample)
JP2016520672A5 (enExample)
ME02861B (me) Postupak za pripremu treprostinila i njegovih derivata
EP3056486A3 (en) Process for preparing intermediates for antiviral compounds
WO2012004396A3 (en) Process of preparing a thrombin specific inhibitor
JP2010530373A5 (enExample)
GB201319253D0 (en) Extraction of carboxylic acids with tin compounds
JP2017524742A5 (enExample)
JO3263B1 (ar) مشتق إندان سلفاميد جديد
EP2736860A4 (en) METHOD FOR THE PRODUCTION OF AROMATIC HYDROCARBONS FROM BYPRODUCTS OF AROMATIC CARBOXYLIC ACID AND / OR METHOD FOR THE PRODUCTION OF AN AROMATIC CARBOXYLIC ALKYL REAGER
RU2017145357A (ru) Пролекарство на основе фосфамида монобензилового сложного эфира тенофовира, способ его получения и применение
JP2014506185A5 (enExample)
WO2012099734A3 (en) Improved process for preparation of low molecular weight molybdenum succinimide complexes
IN2014CN03131A (enExample)
JP2016523246A5 (enExample)
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
SA112330457B1 (ar) مشتقات فينيل- ايزواوكسازول وعملية تحضيرها
JP2018527373A5 (enExample)
EP2684859A4 (en) PROCESS FOR PREPARING FLUOROUS OLEFINS WITH SUBSTITUENTS FROM ORGANIC GROUPS
AR081267A1 (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
JP2016517904A5 (enExample)
UA112407C2 (uk) Співкристали агомелатіну, спосіб їх виготовлення і фармацевтичні композиції, що їх містять
WO2014136047A3 (en) A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
JP2015524456A5 (enExample)